← Back to Clinical Trials
Recruiting NCT07040332

Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Allergic Bronchopulmonary Aspergillosis (ABPA)
Sponsor Qianfoshan Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 140
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-05-10
Completion 2027-07-31

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.

Eligibility Criteria

Inclusion Criteria: * Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis. * Meets the diagnostic criteria for fungal-sensitized asthma. Exclusion Criteria: * Human immunodeficiency virus infection. * Malignant tumor. * Blood system disease. * autoimmune system disease. * History of pulmonary tuberculosis. * Patients with a history of smoking or still smoking. * Invasive pulmonary fungal disease. * Contraindications electronic bronchoscopy

Related Trials

}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology